The value of prostate specific antigen in early diagnosis of prostate cancer: the study of men born in 1913.

[1]  W. Whitmore.  Localised prostatic cancer: management and detection issues , 1994, The Lancet.

[2]  H. Adami,et al.  Ethics of a prostate cancer screening trial , 1994, The Lancet.

[3]  H. Adami,et al.  Screening for prostate cancer: are we ready? , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[4]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[5]  P. Walsh.  Using Prostate-specific Antigen To Diagnose Prostate Cancer: Sailing in Uncharted Waters , 1993, Annals of Internal Medicine.

[6]  P C Prorok,et al.  Prostate Cancer Screening: What We Know and What We Need To Know , 1993, Annals of Internal Medicine.

[7]  M. Benson,et al.  PSA density (PSAD). Role in patient evaluation and management. , 1993, The Urologic clinics of North America.

[8]  R. Eeles,et al.  Prostate cancer Report of a meeting of physicians and scientists, Institute of Cancer Research and the Royal Marsden Hospital , 1993, The Lancet.

[9]  W. Catalona,et al.  Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.

[10]  C G Chute,et al.  Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. , 1993, JAMA.

[11]  O. Nilsson,et al.  Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. , 1993, The Journal of urology.

[12]  M. Garnick,et al.  Prostate Cancer: Screening, Diagnosis, and Management , 1993, Annals of Internal Medicine.

[13]  A S Whittemore,et al.  Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer , 1993, Cancer.

[14]  J. Oesterling,et al.  Clinical Stage B0 or T1c prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration. , 1993, Urology.

[15]  L. Tabár,et al.  Update of the Swedish two-county program of mammographic screening for breast cancer. , 1992, Radiologic clinics of North America.

[16]  G. Chodak,et al.  Routine screening for cancer of the prostate. , 1991, Journal of the National Cancer Institute.

[17]  J. Baron,et al.  The clinical utility of risk factor data. , 1989, Journal of clinical epidemiology.

[18]  T. Stamey,et al.  Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate , 1987 .

[19]  L. Wilhelmsen,et al.  PROSPECTIVE STUDY OF SOCIAL INFLUENCES ON MORTALITY The Study of Men Born in 1913 and 1923 , 1985, The Lancet.

[20]  J. Mandel,et al.  Screening in Chronic Disease , 1985 .

[21]  H. Miller,et al.  Multiple sclerosis. A trial of treatment with tolbutamide. , 1961, Lancet.

[22]  L. M. Franks.  Latent carcinoma of the prostate. , 1954, The Journal of pathology and bacteriology.